Brii Biosciences Ltd (HKSE:02137)

HK$ 1 -0.02 (-1.96%) Market Cap: 730.99 Mil Enterprise Value: -1.84 Bil PE Ratio: 0 PB Ratio: 0.24 GF Score: 29/100

Half Year 2024 Brii Biosciences Ltd Earnings Call Transcript
Aug 20, 2024

HK$0.96 (-2.04%)

Earnings
Brii Biosciences Ltd AASLD Data Readout Investor Call Transcript
Nov 14, 2023
Brii Biosciences Ltd HBV R&D Day Transcript
Aug 24, 2023
Half Year 2023 Brii Biosciences Ltd Earnings Call Transcript
Aug 23, 2023

HK$2.79 (+0.72%)

Earnings
Brii Biosciences Ltd to Discuss VBI Deal and Corporate Update Call Transcript
Jul 06, 2023
Full Year 2022 Brii Biosciences Ltd Earnings Call Transcript
Mar 24, 2023

HK$5.03 (-2.33%)

Earnings
Half Year 2022 Brii Biosciences Ltd Earnings Call Transcript
Aug 24, 2022

HK$7.57 (-3.81%)

Earnings
Full Year 2021 Brii Biosciences Ltd Earnings Call Transcript
Mar 23, 2022

HK$10.84 (-4.24%)

Earnings
Brii Biosciences Ltd Business Update Call: HIV Ph 1 Study Status Transcript
Dec 14, 2021
Half Year 2021 Brii Biosciences Ltd Earnings Call Transcript
Aug 27, 2021

HK$37.6 (+1.21%)

Earnings

Brii Biosciences Ltd HBV R&D Day Transcript

Aug 24, 2023 / 05:00AM GMT

Release Date Price: HK$2.89 (+3.58%)

Transcript

Rico Liang

Brii Biosciences Limited - Senior VP & GM of Greater China

(foreign language) Ladies and gentlemen, good afternoon. Welcome everyone to Brii Biosciences virtual HBV R&D Day. I am today's host, Rico Liang, General Manager of Brii Biosciences, Greater China. On behalf of Brii Biosciences, I would like to express my gratitude to all of you and welcome any questions during the meeting. We will have a Q&A session by the end of the meeting.

Firstly, please allow me to introduce the guest of today. They are Professor Zhuang Hui of Chinese Academy of Engineering; Dr. Hong Zhi, Chairman and CEO of Brii Bio; Dr. Yongqing , China R&D Head of Brii Bio. Thank you so much for your participation. Chronic Hepatitis B is one of the most serious infectious disease in the world with more than 250 million affected people. In particular, China is facing with heavy burden of this disease. Latest administrative research results shows that HBV infection rate in China is 5.6%, covering 79 million people and about 400,000 new infection are related to liver cancer (inaudible) every day. For a

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.